Lytix and Curida: Growth and innovation
Lytix Biopharma and Curida, both Norwegian-owned, have gained attention and acclaim for their innovative approaches and substantial contributions to the healthcare sector.
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 277 entries.
Lytix Biopharma and Curida, both Norwegian-owned, have gained attention and acclaim for their innovative approaches and substantial contributions to the healthcare sector.
De fire helseklyngene gikk denne uka sammen om et høringsinnspill til Stortinget.
A clinical pilot for personalised risk-based breast cancer screening has been conducted as part of the AnteNOR project. Here are some of the results.
During the breakfast seminar The Future of Cancer Politics four politicians discussed possible health- and cancer policies in their coming party programmes. The seminar was held in Norwegian.
Oslo Cancer Cluster Innovation Park opened in May 2015.
The Innovation Park brings together the oncology-value chain from basic research to industry within the Oslo-area.
Our vision is to create Europe's leading environment for education, research and industry within oncology, shortening the development time of new cancer treatments.